CALL FOR PAPERS

Anyone wishing to present a poster at the conference must submit an abstract on one of the topics in this document. All submissions except invited papers must present original work and should not have been published elsewhere.

IMPORTANT: Only papers submitted electronically through IAEA-INDICO can be accepted. Authors are encouraged to submit their abstract as early as possible.

KEY DEADLINES

<table>
<thead>
<tr>
<th>Event</th>
<th>Deadline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic submission of an abstract through INDICO</td>
<td>27 April 2020</td>
</tr>
<tr>
<td>Submission of Forms A and B through official channel</td>
<td>27 April 2020</td>
</tr>
<tr>
<td>Notification of acceptance of abstracts</td>
<td>End of May 2020</td>
</tr>
<tr>
<td>Registration only (submission of Form A through official channel)</td>
<td>No deadline</td>
</tr>
</tbody>
</table>

LANGUAGE

The working language of the conference will be English.

REGISTRATION

No registration fee is charged.

EXHIBITION

A limited amount of space will be available for commercial vendors’ displays/exhibits during the conference. Interested parties should contact the Scientific Secretariat by email at IPET2020@iaea.org before 27 April 2020.
BACKGROUND

The International Atomic Energy Agency (IAEA) is organizing the International Conference on Molecular Imaging and Clinical PET-CT in the Era of Theranostics (IPET-2020) following the successes of IPET-2007, IPET-2011, and IPET-2015.

Nuclear medicine and diagnostic imaging play key roles in cancer management. They permit early and accurate diagnoses and precise staging, provide guidelines for selecting the best course of therapy, allowing the treatment to be monitored, and aid disease management by supporting treatment planning or guided biopsies.

Theranostics is an emerging field and is becoming increasingly essential for the management of various cancers. When labelled with alpha or beta emitters, radiopharmaceuticals can be used for radionuclide-targeted therapies. Medical imaging and radionuclide therapies together help herald the era of personalized medicine.

IPET-2020 will provide a forum for clinicians, imaging specialists, scientists and professionals alike to review the important clinical aspects of cancer management. This conference will critically examine the pivotal role of multimodality imaging techniques, combined with targeted therapies with a view to addressing the health challenges common to many Member States.

OBJECTIVES

The main objectives of the conference are to:

• Review the role of nuclear medicine and diagnostic imaging in the clinical management of patients with prostate, breast, lung, and thyroid cancers, as well as neuroendocrine tumours, lymphoma, and paediatric cancers;
• Review how complementing diagnostic molecular imaging and radionuclide therapies support personalized medicine;
• Review the role of radionuclide therapies in cancer management;
• Highlight current and emerging developments in technology, radiopharmaceuticals, and clinical applications; and
• Provide theoretical tools related to ethics, leadership and education to encourage participants to become future leaders of medical imaging.

AUDIENCE

The target audience includes nuclear medicine physicians, radiologists, technologists and radiographers, medical physicists, radiochemists and radiopharmacists, as well as scientists working in all aspects of molecular imaging.

TOPICS

The IAEA invites participants to provide high-quality contributions on all aspects of nuclear medicine, diagnostic imaging, or theranostic applications and research. Academic and practice-based papers that fall within the following topics are welcome:

• Applications of PET-CT, molecular imaging and diagnostic imaging for different types of cancers;
• Theranostics applications;
• Radio-guided surgery;
• Hybrid imaging and other imaging techniques in benign conditions;
• Dosimetry, physics and instrumentation;
• Radiopharmaceutical production, including good manufacturing practices and quality assurance;
• Radiation protection for personnel and patients;
• Quality management in nuclear medicine and diagnostic imaging;
• Ethics, leadership, and education for nuclear medicine and diagnostic imaging professionals; and
• Experience in establishing or strengthening nuclear medicine, diagnostic imaging or radionuclide therapy facilities, including related technical cooperation projects.